While four big companies from the pharmaceutical segment have already reported their September quarter results, a handful remain yet to report.
Market News and Data brought to you by Benzinga APIsThe following companies have reported their results for the September quarter:
- Abbott Laboratories ABT reported adjusted EPS of $0.59 on revenue of $5.3 billion. While EPS topped by a penny, revenue came in line.
- Eli Lilly and Co LLY reported adjusted EPS of $0.88, revenue of $5.19 billion and missed Street estimates.
- Merck & Co., Inc. MRK reported GAAP EPS of $0.78 and adjusted EPS of $1.07 on revenue of $10.5 billion. Both EPS and revenue topped estimates.
- Novartis AG (ADR) NVS reported core EPS of $1.23 and net sales of $12.13 billion. While EPS topped estimates, revenue fell shy of expectations.
The following companies have yet to announce September quarter results:
- AstraZeneca plc (ADR) AZN is scheduled to disclose its results on November 10. Analysts expect EPS of $0.74 on revenue of $5.91 billion.
- Bristol-Myers Squibb Co BMY is slated to provide results on Thursday. Analysts expect EPS of $0.65 on revenue of $4.79 billion.
- GlaxoSmithKline plc (ADR) GSK will announce its results on Wednesday. The Street is looking for an EPS of $0.74 on revenue of $8.86 billion.
- Pfizer Inc. PFE is scheduled to report on November 1. The Street estimates EPS of $0.62 on revenue of $13.05 billion.
- Sanofi SA (ADR) SNY announces results on Friday. Analysts expect EPS of $0.85 and revenue of $10.69 billion.
- Shire PLC (ADR) SHPG is planning to announce results on November 1. The Street is looking for an EPS of $3.20 and revenue of $3.56 billion.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in